The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

Epirubicin was administered at a dose of 40 mg/m 2 on day 1 and etoposide was administered at a dose of 120 mg/m 2 on days 1, 3 and 5 of each 4-week cycle. Treatment courses were repeated every 4 ...

The objectives of this study were: (1) to conduct a phase II study to assess the efficacy and availability of epirubicin and paclitaxel in the neoadjuvant setting in women with locally advanced or ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

20 Epirubicin (4′-epi-doxorubicin) is synthetic derivative of doxorubicin. Its therapeutic efficacy is similar to that of doxorubicin, but it has a better toxicity profile. 21 Associated adverse ...

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

Tailored dose-dense adjuvant chemotherapy improved long-term outcomes over standard adjuvant chemotherapy in patients with high-risk early breast cancer.

Zydus Lifesciences is one of the biggest names in the pharma business of the country. In a recent development, the company ...

Sterling Biotech is one of the large manufacturers of pharmaceutical gelatin, di-calcium phosphate and APIs including ...

Zydus Lifesciences Ltd on Tuesday said it will acquire the 'Target Business' of Sterling Biotech primarily engaged in ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Zydus Lifesciences has acquired Sterling Biotech's API business, including a fermentation-based API production facility, for ...